1 / 12

Annual report: Generex Biotechnology Corporation

Annual report: Generex Biotechnology Corporation. Aaron Roberson ACG2021. Executive summary. Generex Biotechnology Corporation (Generex) is engaged in the research, development, manufacture and commercialization of drug delivery systems and technologies.

gin
Télécharger la présentation

Annual report: Generex Biotechnology Corporation

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Annual report: Generex BiotechnologyCorporation Aaron Roberson ACG2021

  2. Executive summary • Generex Biotechnology Corporation (Generex) is engaged in the research, development, manufacture and commercialization of drug delivery systems and technologies. • The company focuses on drug delivery system of large molecules in the areas of diabetes, pain management and cancers. It has proprietary and proven advanced technology platform including buccal delivery technology and immunomedicines for the administration of formulations of large molecule drugs to the oral cavity. • Annual Financial Report

  3. Introduction • Chief Executive: AnnaE. Gluskin • Head Office: 33 Harbour Square, Suite 202, Toronto, Canada • Ending date of last fiscal year: July 31 2009 • Geographic area of activity: United States, Canada, Bulgaria, Poland, Romania, Russia and Ukraine • Mission Statement: Our mission is to develop innovative drug delivery technologies and drugs that will improve the quality of life for people who suffer from disease.

  4. Audit Report • Company’s independent auditors: MSCM LLP Toronto, Canada October 6, 2009 • MSCM LLP AUDIT REPORT SUMMARY: The Company’s experience of negative cash flows from operations since inception and its dependency upon future financing raise substantial doubt about its ability to continue as a going concern.   

  5. Stock market information • ‎GNBT- Generex Biotechnology Corporation (NASDAQ)‎ • Current price of stock: $0.62 • 52 week high: 1.14 • 52 week low: 0.08 • Generex Biotechnology has a steady increase in the market thus far, but has shown a trend of poor performance. I would not invest unless I had a desire to help fund research and development for oral pharmaceuticals at the expense of losing money.

  6. Income Statement Generex BioTech Corp has a multi-step income statement. In 2009 Generex Biotech Corp. has increased their net loss by $9,583,237.

  7. Balance Sheet In 2009 Generex BioTech Crop. Decreased its total liabilities and stockholder’s equity which reduced their total assets.

  8. Statement of cash Flows • The Company has experienced negative cash flows from operations since inception and had an accumulated deficit at July 31, 2009 of approximately $294 million. • The Company has funded its activities to date almost exclusively from debt and equity financings. • Generex BioTech had net cash flows from investing activities of $8,698,681 in the year ended July 31, 2009, primarily consisting of $8,852,214 in proceeds from maturity of short term investments. • This was offset by payments for property and equipment of $1,385 and costs incurred for patents of $152,148.

  9. Financial analysis profitability ratios Profit Margin: The company decreased at in increasing rate in profits. Asset Turnover: This low ratio shows the company is inefficient in using its assets. For every sale, this company generates $.31 cents for every dollar's worth of assets.Return on Assets(ROA):ROA gives investors an idea of how effectively the company is converting the money it has to invest into net income. The company is earning less money on more investments. Return on Equity(ROE):ROE shows how well a company uses investment funds to generate earnings growth. This company loses $.13 cents of every dollar given by stockholders.

  10. Financial analysis liquidity ratio Working Capital: The company does not have an abundance of resources to use towards investments. Current Ratio: The Company will be able to pay off its obligations if they were due. They have enough short term assets to cover their short term debts. Receivable Turnover: Its extension of credit and collection of accounts receivable were more efficient in 2009. Inventory Turnover: Shows how many times a company's inventory is sold and replaced over a period. This company has trouble selling its inventory but slightly improved. This is due to the completion ofofficial launch of Generex Oral-lyn™ in India in Jan 2009.

  11. Long term solvency ratio High Debt to Equity means the company has been financing its growth with debt. Which is to be expected for a research company that is in its early stages of development.

  12. Financial analysis market strength ratio • Price/Earnings per share: Current P/E is$-2.64 • Dividend yield: N/A

More Related